2026-02-25 - LD The Hague - GlaxoSmithKline v. Pfizer et al. - UPC_CFI_620/2025, UPC-CFI-0001509/2025, UPC-CFI-0001511/2025
- Aktenzeichen:
- UPC_CFI_620/2025, UPC-CFI-0001509/2025, UPC-CFI-0001511/2025
- Datum:
- Spruchkörper:
- Court of First Instance - The Hague (NL) Local Division
- Art:
- Order
- Parteien:
- GlaxoSmithKline Biologicals SA v. Pfizer et al.
Kernaussage: Companion case management order to UPC_CFI_619/2025 (GSK v Moderna).
2026-02-25 - LD The Hague - GlaxoSmithKline
v.
Pfizer et al. - UPC_CFI_620/2025, UPC-CFI-0001509/2025, UPC-CFI-0001511/2025
routine
Companion case management order to UPC_CFI_619/2025 (GSK v Moderna). The Hague LD panel addressed PBNT's requests regarding GSK's 42 auxiliary requests and 377-page Reply in the COVID-19 vaccine patent case. The court was not convinced that 42 ARs are reasonable and ordered GSK to submit a tabular overview mapping ARs to invalidity attacks, but refused to limit to 10. A one-week deadline extension for the Rejoinder was granted to account for the AR volume. The court reiterated that front-loaded proceedings don't require anticipating every defence — responsive arguments in the Reply are generally permitted. Late-filing claims were dismissed as insufficiently substantiated.